Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current LiabilitiesPayablesPreferred SharesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

NovaBay Pharmaceuticals (NBY) Other Accumulated Expenses (2016 - 2025)

NovaBay Pharmaceuticals (NBY) has disclosed Other Accumulated Expenses for 15 consecutive years, with $31000.0 as the latest value for Q3 2025.

  • On a quarterly basis, Other Accumulated Expenses fell 71.3% to $31000.0 in Q3 2025 year-over-year; TTM through Sep 2025 was $31000.0, a 71.3% decrease, with the full-year FY2024 number at $85000.0, down 62.88% from a year prior.
  • Other Accumulated Expenses was $31000.0 for Q3 2025 at NovaBay Pharmaceuticals, down from $85000.0 in the prior quarter.
  • In the past five years, Other Accumulated Expenses ranged from a high of $480000.0 in Q1 2023 to a low of $31000.0 in Q3 2025.
  • A 5-year average of $236105.3 and a median of $229000.0 in 2023 define the central range for Other Accumulated Expenses.
  • Peak YoY movement for Other Accumulated Expenses: soared 629.17% in 2021, then plummeted 71.3% in 2025.
  • NovaBay Pharmaceuticals' Other Accumulated Expenses stood at $309000.0 in 2021, then surged by 45.95% to $451000.0 in 2022, then tumbled by 49.22% to $229000.0 in 2023, then crashed by 62.88% to $85000.0 in 2024, then plummeted by 63.53% to $31000.0 in 2025.
  • Per Business Quant, the three most recent readings for NBY's Other Accumulated Expenses are $31000.0 (Q3 2025), $85000.0 (Q2 2025), and $100000.0 (Q1 2025).